Q-omics provides the consensus-scored ZMYND10 profile across patient tissues and cancer cell-line models. ZMYND10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZMYND10 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ZMYND10 RNA expression shows 16,254 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KICH, and TGCT as cancer lineages where ZMYND10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMYND10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMYND10 survival associations across molecular data types. ZMYND10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMYND10 RNA expression–survival associations across cancer types. High ZMYND10 expression shows unfavorable associations in ACC, KICH and LGG, but favorable associations in HNSC, KIRP and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZMYND10 RNA expression.
This table summarizes ZMYND10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZMYND10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMYND10 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in COAD, LIHC and BRCA. The KICH box plot shows higher ZMYND10 RNA expression in normal versus tumor tissue (log2 FC = −1.988, t-test p < 0.001).
This table shows molecular features associated with ZMYND10 in patient tissues and cancer cell lines. In patient samples, ZMYND10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMYND10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
